In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

VC Playbook

Set Alert for VC Playbook

Pushing Forward: Venture Capitalist Priorities To Accelerate European Biotech

Sharing his thoughts on the European funding landscape, the importance of software, and sustainable investments, INKEF Capital’s Thijs Cohen Tervaert talks to In Vivo about his investment priorities.

Europe VC Playbook

Bigger Money: Private Equity Grabs European VC

Deals show large investors’ appetite for early-stage biotech, but can VC and PE rub along?

Business Strategies Financing

The Biopharma A List: Taking The Pulse Of Newco Creation

The market for new company creation in the biopharma sector remains healthy and poised to continue fostering the establishment of start-ups, based on a new In Vivo study of the strong initial investments that pharma and biotech companies receive.

StartUps and SMEs Financing

A Guiding Hand For Biotech Start-Ups In Turbulent Times

Rising Leader Therese Liechtenstein is playing an integral part in the creation and financing of multiple companies in the M Ventures portfolio, guiding them towards key value inflection points that a potential partner or acquirer would like to see.

Rising Leaders Financing

From Big Pharma To VC: The Road Travelled By Third Rock’s David Kaufman

VC Playbook: Partner at Third Rock Ventures, David Kaufman, talks to In Vivo about the venture capital firm’s company creation strategy and seeking ‘white space’ in biopharma for innovation. 

C-Suite Speaks Business Strategies

Digital Health Investment In India: Rearing Unicorns

Leaders from HealthQuad, the largest healthtech venture capital fund in India, talk to In Vivo about why the country is a growing and promising market for digital investment. 

Digital Health India

Experience Counts For VC Success: HealthCap Hits 25 Year Mark

VC Playbook: The fundamentals do not change in life sciences investing – good science, unmet need and social responsibility.

VC Playbook Business Strategies

Pfizer Ventures On Striking A Balance Between Strategic And Financial Interests

VC Playbook: Pfizer Ventures senior managing partner Barbara Dalton shares insights into how the corporate venture group balances a dual mandate, the trade-offs needed and what success looks like for a CVC.

VC Playbook Business Strategies

The Microbiome’s Time To Shine

In this installment of our VC Playbook series, In Vivo sits down with Isabelle de Cremoux, CEO of Seventure. The company has been a pioneer investor in the microbiome space, which Cremoux believes has now reached a turning point.

Leadership Financing

Repeat Entrepreneurship And Talent Retention Key To Success Of SV Health Investors

In this latest installment of the VC Playbook series, In Vivo sits down with SV Health Investors’s Houman Ashrafian. The managing partner outlines the group’s investment philosophy, today’s skill set for VC success, and expectations for the future of Britain’s biotech industry post-Brexit and post-pandemic.

Business Strategies Financing

Novo Ventures Remains Bullish After ‘Very Active’ Year

In this latest installment of VC playbook, In Vivo speaks to Naveed Siddiqi, senior partner at Novo Ventures. He discusses the group’s strategy, the European investment outlook for life sciences and how COVID-19 has permanently shifted perceptions of the biopharma industry.

VC Playbook Business Strategies

The New Insider Game In Latin America Biotech

Venture capital funds in Latin America have overlooked biotech, leaving an untapped opportunity for local capital markets and US and European investors alike. Chilean entrepreneur Cristian Hernandez, founder of newly launched boutique VC Zentynel Frontier Investments, explains how business – and society – can benefit from launching biotech start-ups able to serve a global market at lower cost.

VC Playbook South America
See All
UsernamePublicRestriction

Register